GSH catabolism is proposed as a source of amino acids for cells 20,21
If constipation becomes problematic, increasing dietary fibre gradually and considering a gentle laxative such as macrogol (typically first-line per NHS guidance) may help
Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine
Role of fatty acid uptake and fatty acid -oxidation in mediating insulin resistance in heart and skeletal muscle
Sustainable weight loss and metabolic improvements require consistency and a comprehensive approach including nutrition and exercise carnitine is one component, not a quick fix